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Abstract
The concept of ‘cirrhosis’ is evolving and it is now clear that compensated and decompensated cirrhosis are completely dif-
ferent in terms of prognosis. Furthermore, the term ‘advanced chronic liver disease (ACLD)’ better reflects the continuum of
histological changes occurring in the liver, which continue to progress even after cirrhosis has developed, and might regress
after removing the etiological factor causing the liver disease. In compensated ACLD, portal hypertension marks the pro-
gression to a stage with higher risk of clinical complication and requires an appropriate evaluation and treatment. Invasive
tests to diagnose cirrhosis (liver biopsy) and portal hypertension (hepatic venous pressure gradient measurement and en-
doscopy) remain of crucial importance in several difficult clinical scenarios, but their need can be reduced by using different
non-invasive tests in standard cases. Among non-invasive tests, the accepted use, major limitations and major benefits of
serum markers of fibrosis, elastography and imaging methods are summarized in the present review.
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Introduction
Classically, cirrhosis is defined by its histological hallmark find-
ings on liver biopsy (regenerative nodules surrounded by fi-
brotic tissue) and is considered as the final evolution stage of
any progressive liver disease, irrespective of its etiology. The ad-
vances in diagnostic methods allow now early diagnosis, even
before the development of complications, which are mostly
related to development of portal hypertension [1]. Recently,
with the development of new and very effective treatments, es-
pecially in the viral-related cirrhosis scenario, there is increas-
ing evidence that cirrhosis can regress and that histological
improvement is associated with better prognosis [2]. However,
in the particular case of direct acting antiviral (DAA) treatment
of hepatitis C virus (HCV), some data suggest that the complica-
tions of portal hypertension can occur even after sustained viro-
logical response (SVR) and the risk of hepatocellular carcinoma
(HCC) is not abolished [3,4]. Therefore, the international expert
consensus currently suggests continuing screening and surveil-
lance of these patients according to the standard guidelines
used for portal hypertension and HCC, and it is still unknown
whether these patients should be managed and followed ac-
cording to different schemes.
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The natural history of cirrhosis is marked by the transition
from the compensated stage (with good prognosis) to the occur-
rence of decompensation events, such as ascites, variceal
bleeding, jaundice and hepatic encephalopathy. If the diagnosis
of cirrhosis is relatively straightforward during the decompen-
sated stage when the treatment may be problematic, on the
contrary, diagnosing cirrhosis while it is still in the compen-
sated stage is more challenging. The progression of fibrosis par-
allels the increase in portal pressure and, frequently, patients
with severe fibrosis in the pre-cirrhotic stage have a hepatic
venous pressure gradient (HVPG) >5 mmHg [5]. Since chronic
liver disease is a continuum, and due to the inhomogeneity of
fibrosis within the liver [6], the border between severe fibrosis
and compensated cirrhosis is often unclear and, recently, the
Baveno VI consensus recommended that this clinical scenario
including severe fibrosis and initial cirrhosis should be named
compensated advanced chronic liver disease (cACLD) [7].
Moreover, the concept of diagnosis of cirrhosis is changing
from the documentation of histological F4 fibrosis to the identi-
fication of patients truly at risk of developing complications. It
has been clearly demonstrated that the onset of clinically sig-
nificant portal hypertension (defined as HVPG 10 mmHg)
marks the progression to a stage at risk of clinical complica-
tions. In this scenario, non-invasive methods able to mirror the
haemodynamic threshold play an important role. For instance,
according to the recommendations of the last Baveno consen-
sus conference, liver stiffness (measured by transient elastogra-
phy) over 21 kPa is accurate enough to identify patients with
clinically significant portal hypertension, so allowing a simple
and readily available risk stratification when more sophisti-
cated and exact methods are not available [7]. The natural his-
tory of chronic liver disease eventually leading to cACLD and
complications of cirrhosis is represented in Figure 1, together
with the main tests used for its diagnosis, staging and risk
stratification.
In this manuscript, we review the diagnostic performance
of gold-standard invasive methods and surrogate non-
invasive methods used in this setting in light of the new concept
of cACLD.
Gold-standard diagnostic methods for
cirrhosis and portal hypertension
Liver biopsy is still considered the gold-standard diagnostic
method to identify the typical features of cirrhosis. Alternative
diagnostic methods have been validated in comparison to liver bi-
opsy and have a good diagnostic accuracy for the diagnosis of cir-
rhosis. As a consequence, the use of liver biopsy has dramatically
decreased in the last 10 years; nonetheless, it remains a crucial
diagnostic tool when concomitant potential etiological factors for
liver disease coexist and when the identification of features other
than fibrosis leads to changes in the clinical management of pa-
tients, such as in the case of acute or chronic liver injury.
Currently, the most important and frequent scenario that requires
a mandatory liver biopsy is the differentiation between severe al-
coholic hepatitis and decompensated alcoholic cirrhosis, because
by now there are no specific clinical signs or non-invasive meth-
ods to differentiate between the two conditions [8]. Liver biopsy is
largely used in patients with suspected liver cirrhosis of unknown
aetiology in order to confirm the diagnosis and expand on its pos-
sible cause (e.g. indicating the distribution of fibrosis in the liver).
It remains key also in the case of suspected non-alcoholic steato-
hepatitis (NASH)-related ACLD and in cholestatic and autoim-
mune chronic liver disease for which data regarding the
diagnostic accuracy of non-invasive methods are scarce.
Liver biopsy can be carried out from a percutaneous or a
transjugular route. Percutaneous liver biopsy is done through a
right intercostal space after or under ultrasound control, on
local anaesthesia, using Menghini core-aspiration or Tru-cut
automatic 16-gauge needles. Before the procedure, coagulation
parameters should be checked (including platelet count and
prothrombin time/international normalized ratio). The 50/50
rule (prothrombin time over 50% and platelet count over
50  109/L) is frequently used to consider the coagulation and
platelet status acceptable. The contraindications for percutan-
eous liver biopsy include severe coagulopathy, biliary ducts
dilatation, sepsis, ascites, suspicion of vascular lesions, hydatid
disease or uncooperative patient [9]. Some of the contraindica-
tions (especially coagulopathy and ascites) are overcome by
using a transjugular approach that carries lower haemorrhagic
risk. The most frequent indications for liver biopsy are pre-
sented in Table 1 [9,10].
Regarding the diagnostic performance of both approaches,
although previously transjugular liver biopsy was considered
inferior because of the use of thinner needles (18G), there is
strong evidence suggesting that the two techniques are similar
in terms of sample length and the number of complete portal
spaces [11]. The greatest advantage of the transjugular route is
that it allows concomitant HVPG measurement and multiple
passes without increasing the risk of complications.
Liver fibrosis and its patterns remain of paramount import-
ance in risk stratification of patients, even in those who have
fully established liver cirrhosis. Four main patterns of fibrosis
development according to different aetiologies are described:
(i) portal-to-central fibrosis distribution (characteristic to viral
and autoimmune hepatitis); (ii) portal-to-portal distribution
(specific for biliary diseases); (iii) perisinusoidal and pericellular
distribution (metabolic diseases, alcoholic and non-alcoholic
liver diseases) and (iv) central-to-central fibrosis distribution
(for venous outflow obstruction such as Budd-Chiari syndrome)
[12]. According to the different types of fibrosis distribution, the
portal hypertension occurs earlier, as in the case of viral, auto-
immune or Budd-Chiari syndrome, or later in the course of the
disease, as in the case of metabolic diseases. Interestingly, even
Figure 1. Natural history of diagnostic on-invasive diagnostic tests in compen-
sated advanced chronic liver disease. The most appropriate timeframe for using
different techniques in order to maximize the information for clinical use is
given. Combination of different non-invasive unrelated tests can further im-
prove the amount of information retrieved and reduce the risk of false-positive
and false-negative results.
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if sinusoidal portal hypertension develops later in the case of
biliary diseases, due to the portal-to-portal distribution of fibro-
sis and development of porto-portal septa, there is an increased
presinusoidal resistance that will increase portal pressure, so
that the HVPG underestimates the value of the portal pressure
gradient in patients with cholestatic liver disease.
As the disease progress, the amount of fibrosis increases and
in parallel the portal pressure rises [13] corresponding to worsen-
ing in the prognosis [14,15]. The Laennec sub-classification of cir-
rhosis [16] in three subclasses of stage 4: 4A—mild cirrhosis with
thin septa and large nodules; 4B—at least two broad septa, but
no very broad septa and less than half of biopsy length com-
posed of minute nodules; 4C—very broad septum or more than
half of biopsy length composed of minute nodules (micronodular
cirrhosis) offers additional prognosis relevance [17,18]. Moreover,
histological markers of fibrosis regression under therapy, named
‘hepatic repair complex’, can be observed, and consist of delicate
and perforated fibrous septa; isolated and thick collagen fibres;
delicate periportal fibrous spikes; portal tract remnants; hepatic
vein remnants with prolapsed hepatocytes; hepatocytes within
portal tracts or splitting septa; minute regenerative nodules; and
aberrant parenchymal veins [19,20].
Because the majority of complications are conditioned by
portal hypertension occurrence, the measurement of HVPG has
probably an important prognostic relevance that might exceed
that of histological modifications. HVPG is through internal
jugular vein, femoral vein or cubital vein access under local an-
aesthesia [21,22]. One of the hepatic veins is catheterized with a
balloon catheter under fluoroscopic control. By the inflation of
the balloon, the hepatic venous outflow is blocked and, at the
end of 1–2 minutes, the pressure at the tip of the catheter equals
that of the hepatic sinusoidal pressure and portal pressure, re-
spectively. That represents the wedge hepatic venous pressure
(WHVP). Free hepatic venous pressure (FHVP) is measured by
deflating the balloon at 2–3 cm from the hepatic vein ostium,
and usually its value is very close to the inferior vena cava.
HVPG is the difference between WHVP and FHVP, and repre-
sents the pressure gradient that the portal blood flow has to ex-
ceed to pass through the liver. While some authors consider
that FHVP should be substituted by the pressure in the inferior
vena cava or right atrium pressure [23], HVPG loses its prognos-
tic value if it is calculated to any other vessel except the liver
vein, so that FHVP should be mandatorily used [24,25].
Due to the relative invasiveness and the lack of wide diffu-
sion of the method, HVPG is considered by many as only a re-
search method to assess portal pressure but, in the authors’
opinion, it should be considered a crucial and readily available,
mature method to achieve clinically important information. In
clinical practice is a useful technique to make the differential
diagnosis in case of clinical signs of portal hypertension, espe-
cially if cirrhosis is not obvious on non-invasive techniques
such as ultrasound or transient elastography. HVPG is a safe
technique that has no absolute contraindications [26].
In patients requiring transjugular liver biopsy, the measure-
ment of HVPG adds only a few minutes to the procedure but
provides very relevant haemodynamic information. In our prac-
tice, whenever liver biopsy is indicated in patients with cACLD,
we prefer the transjugular approach to obtain both histological
findings and HVPG measurement.
HVPG is probably the most validated tool for assessing prog-
nosis in cACLD. In Table 2 are presented the most relevant clin-
ical end-points with which HVPG was associated [1,5,24,27–33].
All this body of evidence indicates HVPG to be the best tool for
assessing the prognostics of patients with cACLD.
An ideal diagnostic and prognostic method would reflect
also the changes under therapy. A decrease in HVPG <10 mmHg
under non-selective beta-blockers prevents the development of
varices in patients with clinically significant hypertension [29];
in patients with high-risk varices, a decrease to< 12 mmHg or
with 20% from the baseline will prevent first variceal bleeding;
and, in patients who have already suffered variceal bleeding,
the reduction of HVPG below this threshold will prevent
rebleeding [34–37], these patients being considered ‘responders’.
Moreover, in patients with clinically significant hypertension
(HVPG 10 mmHg), without any previous decompensation and
high-risk varices under primary prophylaxis with nadolol,
a 10% decrease in HVPG prevents the development of ascites
[38]. In ‘non-responders’, further decrease in HVPG could be ob-
tained by adding isosorbid-5-mononitrate [39] or shifting from
propranolol to carvedilol [40].
As for the histological modification, portal pressure is
increasing over time in parallel to the worsening of liver
Table 1. The main indications for performing liver biopsy
Percutaneous liver biopsy Transjugular liver biopsy
Diffuse liver diseases with multiple aetiologies Need for parallel measurement of hepatic venous pressure gradient (HVPG)
Abnormal liver test from unknown origin Contraindications to percutaneous access (note that dilatation of the biliary
tree is a contraindication for any liver biopsy)
Non-alcoholic fatty liver disease Suspicion of severe alcoholic hepatitis
Autoimmune hepatitis Acute liver failure of unknown aetiology
Focal lesions Suspicion of non-cirrhotic portal hypertension
Abnormal liver test in haematological patients
Table 2. Different thresholds of hepatic venous pressure gradient
(HVPG) correlated with clinical end-points in compensated advanced
chronic liver disease (cACLD)
HVPG Clinical end-points
<5 mmHg Normal
5–10 mmHg Mild portal hypertension
>6 mmHg Progression of chronic viral hepatitis [5]
High risk of recurrence after liver
transplantation [27]
>10 mmHg Clinically significant portal hypertension
>10 mmHg Oesophageal varices development [28,29]
Ascites [1]
Decompensation [1]
Hepatocellular occurrence [30]
Decompensation after hepatic resection [31]
>12 mmHg Oesofageal varices bleeding
>16 mmHg High mortality [24]
>20 mmHg Failure to control bleeding [32]
>22 mmHg High mortality in severe alcoholic hepatitis [33]
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function, and patients that were considered good ‘responders’
may lose their response to beta-blockers [41]. However, with ef-
fective etiological treatment, portal pressure can improve [42].
At the moment, it is unknown whether clinically significant
hypertension should be seen as a point of ‘no return’ [42,43]. In
this particular context, where liver-stiffness measurement is at
the moment of unclear value, more data about fibrosis and por-
tal pressure dynamics are needed to better understand how pa-
tients who have improved under treatment should be further
managed and, therefore, liver biopsy and HVPG measurement
should be encouraged.
Due to its extensive validation against strong clinical end-
points and since changes in HVPG well reflect changes in prog-
nosis (in terms both of improvement when HVPG decreases and
of worsening when HVPG increases), HVPG is probably the best
surrogate marker of clinical events in patients with cACLD.
Endoscopy
Bleeding from oesophageal varices remains one of the most se-
vere complications of cirrhosis despite the advances in its man-
agement. In order to prevent bleeding from occurring, an
appropriate early diagnosis of oesophageal varices at risk of
bleeding should be achieved. Upper digestive tract endoscopy is
the gold-standard method for diagnosing the presence of gas-
troesophageal varices and identifying signs of risk of bleeding
(large size; red signs). Universal endoscopic screening of oe-
sophageal varices was recommended in all patients newly diag-
nosed with cirrhosis until 2015 [44]. However, due to the
increase in the proportion of patients with early cirrhosis/
cACLD achieved by non-invasive diagnostic methods, this strat-
egy proved to lead to a large number of unnecessary endoscop-
ies [45] that would eventually decrease the patient’s compliance
and increase the health system costs. In the last 10 years,
increasing evidence regarding non-invasive methods (especially
transient elastography) accumulated and proved useful for
stratifying the risk of carrying varices and varices requiring
treatment in patients with cACLD. Based on an acceptable risk
of 5% of missed varices requiring treatment, the 2015 Baveno
consensus conference recommended that patients with normal
platelet count and liver-stiffness measurement by transient
elastography <20 kPa could safely avoid screening endoscopy
[7]. Papers published in full and several abstracts confirmed
that this strategy is safe and allows the sparing of 15–25% of un-
necessary endoscopies. Patients exceeding at least one of these
criteria should undergo screening endoscopy in order to detect
high-risk varices that would benefit from prophylactic treat-
ment. It is important to note that this strategy applies to well-
compensated patients, while patients with decompensated
cirrhosis should undergo endoscopy irrespective of their plate-
let count and liver-stiffness value, due to the much higher risk
of varices requiring treatment in this population [7].
Endoscopy remains needed to identify other signs of portal
hypertension such as hypertensive gastropathy that is often the
cause of minor bleeding in patients with cirrhosis.
Non-invasive serummarkers of fibrosis
Since a long time ago, simple blood tests were used in the diag-
nosis and prognostication of patients with advanced liver dis-
eases. The most largely used is a combination of markers of
liver synthetic function (albumin, bilirubin and prothrombin
time) that, together with two clinical variables (presence and se-
verity of ascites and encephalopathy), constitute the Child-Pugh
score [46]. The possibility of achieving a diagnosis with blood
tests is appealing, since the approach would have an applicabil-
ity close to 100%. Hence, several serum tests including direct
markers of extracellular matrix remodelling and indirect
markers (liver function tests, transaminases, platelet count)
and combined panels/scores have been elaborated on to re-
spond to different clinical questions such as fibrosis staging,
diagnosis of cirrhosis, presence of portal hypertension and
prognosis of patients with cACLD. Table 3 summarizes the most
validated serum tests for diagnosis of cirrhosis and clinically
significant portal hypertension validated in comparison with
HVPG measurement [47–64].
As may be seen, the majority of serum scores are very well
validated for the diagnosis of cirrhosis and could be easily used
according to the local availability. However, as previously
shown, the main cause of complications in patients with cACLD
is clinically significant portal hypertension and this should be
the key diagnostic feature for risk stratification of these pa-
tients. Unfortunately, serum tests are not sufficiently validated
for this purpose and, therefore, none can be used alone for se-
lecting patients who would eventually avoid endoscopy.
Although never used alone, platelet count is probably the most
routinely used test to look for portal hypertension in cACLD.
Low platelet count is very common in patients with cirrhosis,
with 78% of patients developing thrombocytopenia [65], and,
most of the time, it represents a sign of portal hypertension [51].
In the absence of thrombocytopenia, portal hypertension can be
haemodynamically present, but the likelihood of large oesopha-
geal varices is low; a normal platelet count added to< 20 kPa at
liver-stiffness measurement by transient elastography,
screening endoscopy constitutes a simple rule to exclude the
presence of gastroesophageal varices requiring treatment [7].
A valuable non-invasive surrogate should also have prog-
nostic relevance. Simple serum variables as albumin, bilirubin,
prothrombin time and creatinine have been extensively vali-
dated within different prognostic models used to classify cirrho-
sis stage, such as Child-Pugh or MELD (Model for End-stage
Liver Disease) score [66,67]. Only a few of the non-invasive
scores designed to diagnose fibrosis have been tested for prog-
nostic aims. Among them, the enhanced liver fibrosis (ELF) test
and Fibrotest are the most validated, the latter having similar
performance in predicting 5-year survival to liver-stiffness
measurement by transient elastography in a large cohort of
HCV patients [68]; nonetheless, only a minority of patients
included in this study had cirrhosis and, therefore, the results
are difficult to interpret in the context of cACLD.
Elastography
From a physics point of view, elasticity (reciprocal of stiffness)
is defined as the hability of a tissue of maintaining its shape
after being challenged by a mechanical stress. This is an intrin-
sic characteristic of each tissue, and is expressed by the Young’s
elastic module [69,70]. The application of a mechanical stimulus
such as a vibration or an ultrasound impulse to a tissue induces
the formation of shear waves in the tissue itself. These propa-
gate into the tissue with a velocity depending on the tissue elas-
ticity according to the following formula: Elasticity ¼ 3q
(density)  V (propagation velocity) [69,70].
If the amplitude and frequency of the initial stimulus are
known, by using ultrasound or magnetic resonance, it is pos-
sible to measure the velocity of the propagation of the shear
waves and, consequently, it is possible to estimate the elasticity
of a given tissue.
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The healthy liver is an elastic (low-stiffness) organ, while fi-
brosis induces an increase in its stiffness [71,72]. This is the ra-
tionale for the use of elastography methods to estimate fibrosis;
however, it should be underlined that any process occupying
space in the liver tissue (e.g. inflammation, venous congestion,
cholestasis and infiltrative neoplastic processes) and meal in-
gestion increase liver stiffness independently of fibrosis, and
this should be taken into account in the interpretation of elas-
tography results.
Among ultrasound-elastography methods, transient elastog-
raphy (TE; FibroscanVR , Echosens, Paris, France) has been the
first developed to assess liver stiffness. A detailed explanation
of the technical aspects can be found elsewhere [69,70]. TE has
proved to be very accurate in identifying and ruling out cirrhosis
in patients with chronic liver disease of many different aetiolo-
gies (most data have been provided in patients with chronic
viral hepatitis), with an area under the ROC curve (AUC) of 0.94
on meta-analysis [73,74]. Values above 10 kPa are suggestive of
ACLD and values above 12.5 kPa have an accuracy of over 90% in
detecting cirrhosis [75], provided the above-mentioned con-
founders are excluded. Given that liver fibrosis is the major
component of hepatic resistance, and given that hepatic resist-
ance is the major factor leading to portal hypertension in pa-
tients with compensated cirrhosis (Ohm’s law applied to
hydrodynamics: Pressure ¼ Resistance  Flow), liver stiffness
has been tested as a surrogate of portal pressure in cirrhosis.
Interestingly, it was observed that liver stiffness is able to iden-
tify clinically significant portal hypertension with a high accur-
acy (AUC of 0.93 on meta-analysis [76]). Values 21 kPa are
highly specific of clinically significant portal hypertension
[26,51,77] and are associated with increased risk of clinical de-
compensation of cirrhosis and with increased risk of HCC [78].
Despite the fact that liver-stiffness measurement (LSM) is
not an optimal method to identify gastroesophageal varices
[79], it is now accepted that the combination of values of LSM by
TE< 20 kPa and a platelet count >150  109/L can rule out large
oesophageal varices in compensated patients, so leading to a re-
duction in the number of unnecessary endoscopies to screen for
varices [7]. It is important to notice that LSM cannot be used as
a perfect surrogate of HVPG, since, above the threshold of
10–12 kPa, LSM and HVPG are no longer strictly correlated [80].
Furthermore, LSM changes in patients on non-selective beta-
blockers do not mirror changes in HVPG and TE cannot be used
to monitor the haemodynamic response to beta-blockers.
Other newer ultrasound-elastography methods that are
incorporated in standard ultrasound equipments include point
shear-wave elastography (pSWE; taking advantage of acoustic
radiation force impulse imaging) and two-dimensional shear-
wave elastography (2D-SWE) [69,70]. These techniques allow
visualizing in real time the area where the measurement of
elastic-wave velocity is performed; the measurement needs to
follow reliability criteria based on the quality of the ultrasound
image and the result is given either as metres/second or as kPa.
The first pSWE available in the market (VirtualTouch, Siemens,
Germany) is now considered validated and provides a higher
applicability for the measurement of liver stiffness as compared
to TE, with similar accuracy for detecting liver cirrhosis [81]; the
suggested cut-off is 1.80–1.85 m/sec. The first 2D-SWE available
in the market (Aixplorer, Supersonic Imagine, France) is close to
validation; its applicability and diagnostic performance seem
comparable to those of TE [82]. The suggested cut-off for cirrho-
sis is 11.5 kPa.
Limited data are available regarding the accuracy of pSWE
and 2D-SWE for portal hypertension, but pilot experiences sug-
gest that these methods yield similar results as compared to TE
[83].
Since the spleen in patients with cirrhosis undergoes en-
largement and changes mostly related to portal hypertension
[84], spleen-stiffness measurement (SSM) has been proposed as
a novel parameter, not yet routinely used, to better mirror portal
hypertension as compared to LSM [83]. In the first studies using
TE, SSM showed a close correlation to HVPG and, in a meta-
analytic review of 16 studies performed by different ultrasound-
elastography methods, SSM was superior to LSM to predict the
presence of oesophageal varices [85]. SSM by using TE has sub-
stantial limitations, including low applicability in normal-sized
spleens and a ceiling effect at 75 kPa, limiting risk stratification
above this threshold.
Magnetic resonance elastography (MRE) has been proposed
as a method to evaluate both liver and spleen stiffness, over-
coming some of the limitations of ultrasound-elastography
methods (no need for an acoustical window, freely oriented
field of view, lack of sensitivity to body habitus) [86,87]. MRE has
proved to be accurate in stage of liver fibrosis (being marginally
better than TE and pSWE in two studies [88,89]) and is a highly
promising method for diagnosing cirrhosis in patients unsuit-
able to ultrasound elastography. It holds high reproducibility
and, interestingly, changes in MRE correlate with changes in
fibrosis.
Recently, Ronot et al used multiparametric MRE in a small
series of 36 patients on the waiting list for orthotopic liver trans-
plantation undergoing HVPG measurement and endoscopy [90].
Three different liver and spleen parameters were assessed,
namely storage, loss and shear moduli. The spleen loss
Table 3. Serum tests used for diagnosis of cirrhosis and portal hypertension
Indirect serum test
Platelet count Very well validated [47–49] Very well validated [50,51]
ALT/AST index Few evidences [49,52] No evidence
AST/platelet ratio index Very well validated [49,53,54] No evidence
Lok Well validated [49,55] Little evidence [56]
FIB-4 Very well validated [57–59] Little evidence [56]
Forns Little evidence [60] No evidence
Direct fibrosis markers included
Fibrotest Very well validated [61–63] Little evidence [50]
Fibrometer Very well validated [62,63] No evidence
Hepascore Very well validated [62,63] No evidence
Hyaluronic acid Very well validated [57,64] No evidence
Enhanced liver fibrosis Very well validated [63,64] No evidence
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modulus was the best parameter for identifying patients with
severe portal hypertension (AUC ¼ 0.81, p ¼ 0.019) or high-risk
varices (AUC ¼ 0.93, p ¼ 0.042), confirming previous data regard-
ing the potential of spleen stiffness on the evaluation of portal
hypertension in cirrhosis.
Limitations of MRE include its high cost and limited avail-
ability, which currently prevent its use as a routine diagnostic
method.
Imaging methods
Ultrasound
Ultrasound is the first-line imaging examination to be per-
formed in patients with suspected cirrhosis and/or portal
hypertension. Ultrasound is safe, can be repeated easily, is not
expensive and is highly sensitive in detecting thrombosis in the
portal vein and hepatic veins, so allowing a correct differential
diagnosis of new cases of portal hypertension [91]. As for the
limitations, inter-observer variability is considered a major
drawback, but appropriate training and knowledge markedly re-
duce it. Intestinal gas and obesity limit the exploration.
Ultrasound signs of cirrhosis on grey-scale (B mode) include
changes in liver morphology and signs of portal hypertension
(Table 4). Most signs have a high specificity and can be con-
sidered sufficient to confirm the diagnosis of cirrhosis. On the
other hand, the sensitivity of most individual signs is low, indi-
cating that a negative result cannot fully rule out cirrhosis in pa-
tients with compensated chronic liver disease.
The most accurate single sign for the diagnosis of cirrhosis,
which can be found even in early phases and should be always
specifically investigated, is nodularity of the liver surface
[92,93]. The use of high-frequency transducers increases the
diagnostic performance of conventional abdominal ultrasound
probes and should be preferred [92,93]. False-positive findings
are rare but have been described (e.g. fulminant hepatitis lead-
ing to the collapse of large parenchyma areas). The combination
of nodular liver surface and portal vein mean velocity below
12 cm/sec holds an accuracy of 80% for discriminating between
patients with chronic hepatitis with severe fibrosis and those
with cirrhosis [94]. In patients with clinical suspicion of cirrho-
sis and confounding conditions, the detection of nodular liver
surface is an excellent non-invasive method to rule in cirrhosis,
while the combination of ultrasound and TE allows the best
diagnostic performance [93].
Similarly to what has previously been discussed regarding
cirrhosis, most ultrasound signs of portal hypertensions are
specific, but their sensitivity is moderate, especially in compen-
sated cirrhosis; therefore, while the presence of a sign or a com-
bination of signs permits confirming portal hypertension, the
absence of ultrasound signs cannot exclude this diagnosis
[95,96]. Only two signs are 100% specific (pathognomonic) signs
of portal hypertension, namely porto-systemic collaterals (e.g.
paraumbilical vein, spleno-renal collaterals, etc.) and reversal of
flow in the portal vein system.
Splenomegaly is commonly associated with portal hyperten-
sion; this sign is more sensitive than other signs, but less spe-
cific. However, increasing spleen size is an independent
predictor of gastroesophageal varices in compensated cirrhosis
[51].
Other signs include dilatation of the portal venous system
vessels, lack of or reduced respiratory variations of splenic and
superior mesenteric vein diameter, reduced portal vein velocity,
increased congestion index of the portal vein and an altered
Doppler pattern in the liver veins. Less commonly explored
signs include changes in the arterial flow pattern of the hepatic,
splenic, mesenteric and renal arteries.
Despite the fact that most of these signs show some degree
of correlation with the HVPG, none of them can be used as a re-
liable surrogate for haemodynamic measurement either at first
examination or after starting non-selective beta-blocker ther-
apy. Nonetheless, ultrasound parameters hold prognostic value
and can suggest a worsening of portal hypertension on follow-
up [95,96]. For instance, the development of or increase in the
number of visible porto-systemic collaterals and progressive
spleen size increase are associated with variceal formation and
growth. Finally, Doppler ultrasound can be used to follow up the
patency of transjugular intrahepatic porto-systemic shunt
(TIPS) and proved useful to save unnecessary invasive
haemodynamic procedures [97].
Computed tomography (CT) and magnetic resonance
imaging (MRI)
Most of the signs mentioned in the ultrasound section suggest
cirrhosis on other cross-sectional imaging (Table 4) [98]; follow-
ing an approach first suggested by our group on ultrasound
images [93], it has been recently described that the quantitative
measurement of liver surface nodularity from routine CT
images in the portal venous phase is accurate in differentiating
Table 4. Most commonly observed signs of cirrhosis on imaging
Liver morphology changes Nodular liver surface (all imaging methods, but better visualized by high-frequency probe on ultrasound)
Coarse echopattern (ultrasound); heterogeneous density with nodular pattern in some cases (CT)
Hypertrophy of the left lobe and atrophy of the segment IV (better visualized on CT and MRI); expanded
gallbladder fossa (CT and MRI)
Hypertrophy of caudate lobe
Reduction of the medial segment of left hepatic lobe
Hepatic veins Narrowing and loss of normal plasticity of flow by Doppler
Altered straightness
Non-uniformity of hepatic vein-wall echogenicity
Hepatic artery Increased diameter (all techniques) and tortuosity (CT)
Portal venous system Dilatation of portal vein (13 mm), splenic vein and superior mesenteric vein (11 mm)
Reduction of portal vein blood-flow velocity
Reversal of portal vein blood flow
Spleen Increased size (splenomegaly: diameter >12 cm and/or area 45 cm2 by ultrasound)
Presence of porto-systemic collateral circulation
Minimal perihepatic ascites
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cirrhosis from non-cirrhotic livers [99]. If validated, this meas-
urement could be implemented routinely in patients with
chronic liver disease undergoing CT.
Contrast-enhanced cross-sectional imaging allows very ac-
curate visualization of the portal venous system and of the
porto-systemic collaterals, so potentially providing useful data
to detect oesophageal varices. However, while large oesopha-
geal varices can be reliably diagnosed by single- or multidetec-
tor CT (sensitivity 84–100%; specificity 90–100%), inter-observer
reproducibility is moderate and the sensitivity of the method
for the detection of small varices is low. Due to these limita-
tions, endoscopic screening is more cost-effective than
contrast-enhanced CT followed by endoscopic screening in
positive cases [100].
Dynamic contrast-enhanced techniques on CT and MRI
(compartmental analysis of intensity versus time curves for
magnetic resonance images of the liver after injection of a gado-
linium chelate; phase contrast MR angiography) allow quantita-
tive measurement of perfusion [101] and portal and azygos
blood flow [102,103]. In one paper, HVPG correlated with a portal
fraction of liver perfusion [104] and, in another, it correlated
with azygos blood flow [105]; the latter parameter weakly correl-
ates with the presence of oesophageal varices. In recent work,
the combination of longitudinal relaxation time (T1) of the liver
and splenic artery velocity remained independently associated
with HVPG [106]. Future studies should address the practical
use and the cost-effectiveness of these possible predictors in
clinical practice.
Conclusions and future directions
As shown in the present review, it is currently possible to diag-
nose liver cirrhosis and portal hypertension accurately by non-
invasive methods in a fair proportion of patients with chronic
liver disease. However, all methods have pros and cons
(Table 5). New, more sophisticated non-invasive diagnostic
methods such as MRE, new software analysis of images ob-
tained with the existing technology such as the analysis of the
nodularity of liver surface on ultrasound [93] and CT images [99]
and dynamic techniques on MRI are emerging tools further im-
proving this possibility. Nonetheless, it should be remembered
that an accurate diagnosis requires not only practical skills and
specific knowledge of the methods to be used, however, but also
clinical experience and critical judgment to identify potential
false negatives and false positives of the tests used. In this con-
text, liver biopsy is and will continue to be a crucial tool for pa-
tients in whom the clinical features are not typical, in whom
the results of non-invasive tests are discordant and in acquiring
better knowledge of the natural history/regression of cACLD
after effective cure of the cause leading to cirrhosis.
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